About us
Services
Science Hub
News & Events
Investors
Contact us
EN

Science News
Resources

Bispecific antibodies

Many lifesaving biopharmaceuticals are suffering from a slump in venture funding. Novel recombinant protein based therapeutics, but also biosimilars are needed to fill the gaps in unmet patient needs. At Mabion we understand how to advance promising biosimilars and novel biotherapeutics to the clinic and from there to patients. Unfortunately, many promising biopharmaceutical innovations spanning novel recombinant protein therapeutics to biosimilars are being held back in the current, limiting funding climate, depriving patients from access to advanced therapies. Yet the urgency to close gaps in unmet patient care has never been greater. That is why we are launching the “Unlocking the Future of Therapeutics” competition a unique opportunity to support and accelerate biologics development and scale up for an oncology-targeted therapeutic. We are offering €500,000 credit in development services to support an exceptional therapeutic project. This can be a novel therapeutic, but might also be a biosimilar drug which expands patients access to lifesaving care. We have partnered with respected academic experts focused on cancer research to select the most promising candidate.

Mabion Launches €500,000 Services Contest to Support Next-Gen Oncology Breakthroughs

Bispecifics antibodies: The next big thing in lymphoma treatment

Bispecific antibodies: success story continues

Contact

Find out how we may support your business.

Mabion

gen. Mariana Langiewicza 60
95-050 Konstantynów Łódzki
Poland

+48 42 207 78 90

By sending the contact form, I declare that I have read the privacy policy available at this link.

Privacy policy
Services
Investors
News&Events
Contact us

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. Page Sitemap

Powered by